Infection Control Practice in Cystic Fibrosis Centers

Clinics in Chest Medicine

Volumn 28, Issue 2, 2007, Pages 381-404

  Zuckerman, Jonathan B ^a,b   Seder, David B ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TRANSMISSION; BURKHOLDERIA; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DISINFECTION; HOSPITAL PATIENT; HUMAN; INFECTION CONTROL; MEDICAL PRACTICE; OUTPATIENT CARE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW;

CYSTIC FIBROSIS; DRUG RESISTANCE, MICROBIAL; HUMANS; INFECTION CONTROL; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; UNIVERSAL PRECAUTIONS;

EID: 34247539525     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2007.02.010     Document Type: Review

References (186)

1. Cystic Fibrosis Foundation patient registry 2005. Cystic Fibrosis Foundation. Bethesda (MD); 2006.
2. Moore J.E., et al. Infection control and the significance of sputum and other respiratory secretions from adult patients with cystic fibrosis. Ann Clin Microbiol Antimicrob 3 (2004) 8-12
3. Isles A., et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 104 2 (1984) 206-210
4. Hardy K.A., et al. Pseudomonas cepacia in the hospital setting: lack of transmission between cystic fibrosis patients. J Pediatr 109 1 (1986) 51-54
5. Thomassen M.J., et al. Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis. Am Rev Respir Dis 134 4 (1986) 669-671
6. LiPuma J.J., et al. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 336 8723 (1990) 1094-1096
7. Pegues D.A., et al. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group. J Pediatr 124 5 Pt 1 (1994) 694-702
8. Johnson W.M., Tyler S.D., and Rozee K.R. Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol 32 4 (1994) 924-930
9. Govan J.R., et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 342 8862 (1993) 15-19
10. Jones A.M., Dodd M.E., and Webb A.K. Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J 17 2 (2001) 295-301
11. Holmes A., et al. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis 179 5 (1999) 1197-1205
12. Ledson M.J., et al. Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia. Thorax 53 5 (1998) 432-436
13. Aris R.M., et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex: survival linked to genomovar type. Am J Respir Crit Care Med 164 11 (2001) 2102-2106
14. Chaparro C., et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 163 1 (2001) 43-48
15. Webb A.K., and Egan J. Should patients with cystic fibrosis infected with Burkholderia cepacia undergo lung transplantation?. Thorax 52 8 (1997) 671-673
16. Chen J.S., et al. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 139 5 (2001) 643-649
17. Speert D.P., et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am J Respir Crit Care Med 166 7 (2002) 988-993
18. Whiteford M.L., et al. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax 50 11 (1995) 1194-1198
19. Segonds C., et al. Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates. J Clin Microbiol 37 7 (1999) 2201-2208
20. LiPuma J.J., et al. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 164 1 (2001) 92-96
21. Biddick R., et al. Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett 228 1 (2003) 57-62
22. Vermis K., et al. Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int J Syst Evol Microbiol 54 Pt 3 (2004) 689-691
23. Kalish L.A., et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 173 4 (2006) 421-425 [Epub 2005 Nov 4]
24. Duff A.J. Psychological consequences of segregation resulting from chronic Burkholderia cepacia infection in adults with CF. Thorax 57 9 (2002) 756-758
25. Geddes D.M. Of isolates and isolation: Pseudomonas aeruginosa in adults with cystic fibrosis. Lancet 358 9281 (2001) 522-523
26. Williams T. Evaluation of antimicrobial sensitivity patterns as markers of Pseudomonas aeruginosa cross-infection at a cystic fibrosis clinic. Br J Biomed Sci 54 3 (1997) 181-185
27. Tenover F.C., et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33 9 (1995) 2233-2239
28. Sener B., et al. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. Int J Med Microbiol 291 5 (2001) 387-393
29. Harris A., et al. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 28 5 (1999) 1128-1133
30. Struelens M.J., et al. Genome macrorestriction analysis of diversity and variability of Pseudomonas aeruginosa strains infecting cystic fibrosis patients. J Clin Microbiol 31 9 (1993) 2320-2326
31. Grothues D., et al. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol 26 10 (1988) 1973-1977
32. Saiman L., and Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 24 5 Suppl (2003) S6-S52
33. Renders N., Verbrugh H., and Van Belkum A. Dynamics of bacterial colonisation in the respiratory tract of patients with cystic fibrosis. Infect Genet Evol 1 1 (2001) 29-39
34. Hoiby N. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. Paediatr Drugs 2 6 (2000) 451-463
35. West S.E., et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 287 22 (2002) 2958-2967
36. Martin D.W., et al. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci U S A 90 18 (1993) 8377-8381
37. Worlitzsch D., et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109 3 (2002) 317-325
38. Govan J.R., and Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60 3 (1996) 539-574
39. Pedersen S.S. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis. APMIS Suppl 28 (1992) 1-79
40. Romling U., et al. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis 170 6 (1994) 1616-1621
41. Kerem E., et al. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 116 5 (1990) 714-719
42. Kosorok M.R., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 32 4 (2001) 277-287
43. Henry R.L., Mellis C.M., and Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 12 3 (1992) 158-161
44. Lechtzin N., et al. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 73 1 (2006) 27-33 [Epub 2005 Aug 17]
45. Jones A.M., et al. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 57 11 (2002) 924-925
46. Al-Aloul M., et al. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 59 4 (2004) 334-336
47. Zembrzuska-Sadkowska E., et al. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in the Danish Cystic Fibrosis Centre. J Hosp Infect 29 1 (1995) 1-7
48. Tubbs D., et al. Pseudomonas aeruginosa in cystic fibrosis: cross-infection and the need for segregation. Respir Med 95 2 (2001) 147-152
49. da Silva Filho L.V., et al. Molecular epidemiology of Pseudomonas aeruginosa infections in a cystic fibrosis outpatient clinic. J Med Microbiol 50 3 (2001) 261-267
50. Kerr J.R., et al. Evidence against transmission of Pseudomonas aeruginosa by hands and stethoscopes in a cystic fibrosis unit. J Hosp Infect 50 4 (2002) 324-326
51. Laraya-Cuasay L.R., Cundy K.R., and Huang N.N. Pseudomonas carrier rates of patients with cystic fibrosis and of members of their families. J Pediatr 89 1 (1976) 23-26
52. Tummler B., et al. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol 29 6 (1991) 1265-1267
53. Bosshammer J., et al. Comparative hygienic surveillance of contamination with pseudomonads in a cystic fibrosis ward over a 4-year period. J Hosp Infect 31 4 (1995) 261-274
54. Ojeniyi B., Frederiksen B., and Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 29 3 (2000) 177-181
55. McCallum S.J., et al. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet 358 9281 (2001) 558-560
56. Jones A.M., et al. Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak. Thorax 58 6 (2003) 525-527
57. Panagea S., et al. Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces. J Hosp Infect 59 2 (2005) 102-107
58. Scott F.W., and Pitt T.L. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol 53 Pt 7 (2004) 609-615
59. Farrell P.M., et al. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics 100 5 (1997) E2
60. Kosorok M.R., et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol 26 2 (1998) 81-88
61. Frederiksen B., Koch C., and Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 28 3 (1999) 159-166
62. Pedersen S.S., et al. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 17 4 (1986) 505-516
63. Griffiths A.L., et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am J Respir Crit Care Med 171 9 (2005) 1020-1025 [Epub 2005 Feb 11]
64. Jones A.M., et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center. Am J Respir Crit Care Med 171 3 (2005) 257-260 [Epub 2004 Nov 12]
65. Boukadida J., et al. Molecular epidemiology of chronic pulmonary colonisation by Pseudomonas aeruginosa in cystic fibrosis. J Med Microbiol 38 1 (1993) 29-33
66. Hoogkamp-Korstanje J.A., et al. Risk of cross-colonization and infection by Pseudomonas aeruginosa in a holiday camp for cystic fibrosis patients. J Clin Microbiol 33 3 (1995) 572-575
67. Cheng K., et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 348 9028 (1996) 639-642
68. Adams C., et al. Epidemiology and clinical impact of Pseudomonas aeruginosa infection in cystic fibrosis using AP-PCR fingerprinting. J Infect 37 2 (1998) 151-158
69. Jones A.M., et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 358 9281 (2001) 557-558
70. Goering R.V., et al. Staphylococcus aureus in patients with cystic fibrosis: an epidemiological analysis using a combination of traditional and molecular methods. Infection 18 1 (1990) 57-60
71. Foca M., et al. Endemic Pseudomonas aeruginosa infection in a neonatal intensive care unit. N Engl J Med 343 10 (2000) 695-700
72. Doring G., et al. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol 21 2 (1996) 90-100
73. Barth A.L., and Pitt T.L. The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa. J Med Microbiol 45 2 (1996) 110-119
74. Zimakoff J., et al. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect 4 1 (1983) 31-40
75. Doring G., et al. Generation of Pseudomonas aeruginosa aerosols during handwashing from contaminated sink drains, transmission to hands of hospital personnel, and its prevention by use of a new heating device. Zentralbl Hyg Umweltmed 191 5-6 (1991) 494-505
76. Anaissie E.J., Penzak S.R., and Dignani M.C. The hospital water supply as a source of nosocomial infections: a plea for action. Arch Intern Med 162 13 (2002) 1483-1492
77. Jensen E.T., et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment. J Hosp Infect 36 2 (1997) 117-122
78. Rosenfeld M., et al. Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough?. J Hosp Infect 49 3 (2001) 229-230
79. Pitchford K.C., et al. Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment. J Pediatr 111 2 (1987) 212-216
80. Jakobsson B.M., et al. Low bacterial contamination of nebulizers in home treatment of cystic fibrosis patients. J Hosp Infect 36 3 (1997) 201-207
81. Jakobsson B., Hjelte L., and Nystrom B. Low level of bacterial contamination of mist tents used in home treatment of cystic fibrosis patients. J Hosp Infect 44 1 (2000) 37-41
82. Berrouane Y.F., et al. Outbreak of severe Pseudomonas aeruginosa infections caused by a contaminated drain in a whirlpool bathtub. Clin Infect Dis 31 6 (2000) 1331-1337 [Epub 2000 Nov 29]
83. Kuehnert M.J., et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 193 2 (2006) 172-179 [Epub 2005 Dec 15]
84. Kirby W. Extraction of a highly potent penicillin inactivator from penicillin resistant Staphylococci. Science 99 2579 (1944) 452-453
85. Barber M. Methicillin-resistant staphylococci. J Clin Pathol 14 (1961) 385-393
86. Hackbarth C.J., and Chambers H.F. Methicillin-resistant staphylococci: genetics and mechanisms of resistance. Antimicrob Agents Chemother 33 7 (1989) 991-994
87. Katayama Y., Zhang H.Z., and Chambers H.F. PBP 2a mutations producing very-high-level resistance to beta-lactams. Antimicrob Agents Chemother 48 2 (2004) 453-459
88. Boxerbaum B., Jacobs M.R., and Cechner R.L. Prevalence and significance of methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. Pediatr Pulmonol 4 3 (1988) 159-163
89. Saravolatz L.D., Pohlod D.J., and Arking L.M. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Ann Intern Med 97 3 (1982) 325-329
90. Creech II C.B., et al. Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J 24 7 (2005) 617-621
91. Phaff S.J., et al. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 57 4 (2006) 741-746 [Epub 2006 Feb 9]
92. Prunier A.L., et al. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob Agents Chemother 46 9 (2002) 3054-3056
93. Prunier A.L., et al. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 187 11 (2003) 1709-1716 [Epub 2003 May 15]
94. Goerke C., et al. Molecular epidemiology of community-acquired Staphylococcus aureus in families with and without cystic fibrosis patients. J Infect Dis 181 3 (2000) 984-989
95. Branger C., Gardye C., and Lambert-Zechovsky N. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. J Med Microbiol 45 4 (1996) 294-301
96. Miall L.S., et al. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 84 2 (2001) 160-162
97. Liou T.G., et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 153 4 (2001) 345-352
98. Looney W.J. Small-colony variants of Staphylococcus aureus. Br J Biomed Sci 57 4 (2000) 317-322
99. Schlichting C., et al. Typing of Staphylococcus aureus by pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships. J Clin Microbiol 31 2 (1993) 227-232
100. Givney R., et al. Methicillin-resistant Staphylococcus aureus in a cystic fibrosis unit. J Hosp Infect 35 1 (1997) 27-36
101. Renders N.H., et al. Molecular epidemiology of Staphylococcus aureus strains colonizing the lungs of related and unrelated cystic fibrosis patients. Clin Microbiol Infect 3 2 (1997) 216-221
102. Nadesalingam K., Conway S.P., and Denton M. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. J Cyst Fibros 4 1 (2005) 49-52
103. Burkholder W.H. Sour skin, a bacterial rot of onion bulbs. Phytopathology 40 (1950) 115-117
104. Holmes A., Govan J., and Goldstein R. Agricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health?. Emerg Infect Dis 4 2 (1998) 221-227
105. Ramette A., LiPuma J.J., and Tiedje J.M. Species abundance and diversity of Burkholderia cepacia complex in the environment. Appl Environ Microbiol 71 3 (2005) 1193-1201
106. Moore J.E., et al. Occurrence of Burkholderia cepacia in foods and waters: clinical implications for patients with cystic fibrosis. J Food Prot 64 7 (2001) 1076-1078
107. LiPuma J.J., and Mahenthiralingam E. Commercial use of Burkholderia cepacia. Emerg Infect Dis 5 2 (1999) 305-306
108. Estivariz C.F., et al. An outbreak of Burkholderia cepacia associated with contamination of albuterol and nasal spray. Chest 130 5 (2006) 1346-1353
109. Miller S.C., LiPuma J.J., and Parke J.L. Culture-based and non-growth-dependent detection of the Burkholderia cepacia complex in soil environments. Appl Environ Microbiol 68 8 (2002) 3750-3758
110. Lessie T.G., et al. Genomic complexity and plasticity of Burkholderia cepacia. FEMS Microbiol Lett 144 2-3 (1996) 117-128
111. Vandamme P., and Vanlaere E. Taxonomy and epidemiology of B. cepacia complex: where are we now?. Pediatr Pulmonol S29 (2006) 114-115
112. Winkelstein J.A., et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 79 3 (2000) 155-169
113. Reik R., Spilker T., and Lipuma J.J. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol 43 6 (2005) 2926-2928
114. Martin D.W., and Mohr C.D. Invasion and intracellular survival of Burkholderia cepacia. Infect Immun 68 1 (2000) 24-29
115. Schwab U., et al. Patterns of epithelial cell invasion by different species of the Burkholderia cepacia complex in well-differentiated human airway epithelia. Infect Immun 70 8 (2002) 4547-4555
116. Baird R.M., et al. Burkholderia cepacia is resistant to the antimicrobial activity of airway epithelial cells. Immunopharmacology 44 3 (1999) 267-272
117. Maschmeyer G., and Gobel U.B. Stenotrophomonas maltophilia and Burkholderia cepacia. In: Mandel G.L., Bennett J.E., and Dolin R. (Eds). Principles and Practices of Infectious Diseases (2005), Elsevier, Philadelphia 2515-2522
118. McMenamin J.D., et al. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest 117 6 (2000) 1661-1665
119. Coenye T., and LiPuma J.J. Molecular epidemiology of Burkholderia species. Front Biosci 8 (2003) e55-e67
120. LiPuma J.J. Burkholderia cepacia: management issues and new insights. Clin Chest Med 19 3 (1998) 473-486 vi
121. Ledson M.J., et al. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax 57 2 (2002) 142-145
122. Corey M., and Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 143 10 (1996) 1007-1017
123. Courtney J.M., et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 3 2 (2004) 93-98
124. Liou T.G., Adler F.R., and Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med 171 9 (2005) 1053-1059 [Epub 2005 Feb 1]
125. Blackburn L., et al. 'Cepacia syndrome' with Burkholderia multivorans, 9 years after initial colonization. J Cyst Fibros 3 2 (2004) 133-134
126. Cunha M.V., et al. Molecular analysis of Burkholderia cepacia complex isolates from a Portuguese cystic fibrosis center: a 7-year study. J Clin Microbiol 41 9 (2003) 4113-4120
127. Lipuma J.J. Which is the "Bad Cepacia"?. Pediatr Pulmonol S29 (2006) 118-119
128. Pegues D.A., et al. Possible nosocomial transmission of Pseudomonas cepacia in patients with cystic fibrosis. Arch Pediatr Adolesc Med 148 8 (1994) 805-812
129. Tablan O.C., et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis: risk factors and outcomes. Chest 91 4 (1987) 527-532
130. Burdge D.R., Nakielna E.M., and Noble M.A. Case-control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis. Infect Control Hosp Epidemiol 14 3 (1993) 127-130
131. LiPuma J.J., et al. Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers. J Pediatr 113 5 (1988) 859-862
132. Smith D.L., et al. Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission. J Clin Microbiol 31 11 (1993) 3017-3022
133. Sun L., et al. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med 1 7 (1995) 661-666
134. Mahenthiralingam E., et al. Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. J Clin Microbiol 34 12 (1996) 2914-2920
135. Segonds C., et al. Genotypic analysis of Burkholderia cepacia isolates from 13 French cystic fibrosis centers. J Clin Microbiol 35 8 (1997) 2055-2060
136. Clode F.E., Metherell L.A., and Pitt T.L. Nosocomial acquisition of Burkholderia gladioli in patients with cystic fibrosis. Am J Respir Crit Care Med 160 1 (1999) 374-375
137. Speert D.P., et al. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis 8 2 (2002) 181-187
138. Campana S., et al. Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy. J Clin Microbiol 43 10 (2005) 5136-5142
139. Mahenthiralingam E., Simpson D.A., and Speert D.P. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol 35 4 (1997) 808-816
140. Sajjan U.S., and Forstner J.F. Role of a 22-kilodalton pilin protein in binding of Pseudomonas cepacia to buccal epithelial cells. Infect Immun 61 8 (1993) 3157-3163
141. McDowell A., et al. Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation. J Med Microbiol 53 Pt 7 (2004) 663-668
142. Ramsey A.H., et al. Burkholderia cepacia lower respiratory tract infection associated with exposure to a respiratory therapist. Infect Control Hosp Epidemiol 22 7 (2001) 423-426
143. Hutchinson G.R., et al. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol 34 3 (1996) 584-587
144. Hamill R.J., et al. An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med 122 10 (1995) 762-766
145. Reboli A.C., et al. An outbreak of Burkholderia cepacia lower respiratory tract infection associated with contaminated albuterol nebulization solution. Infect Control Hosp Epidemiol 17 11 (1996) 741-743
146. Gravel D., et al. Outbreak of Burkholderia cepacia in the adult intensive care unit traced to contaminated indigo-carmine dye. Infect Control Hosp Epidemiol 23 2 (2002) 103-106
147. Saiman L., and Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev 17 1 (2004) 57-71
148. Saiman L., et al. Infection control in cystic fibrosis: practical recommendations for the hospital, clinic, and social settings. Am J Infect Control 28 5 (2000) 381-385
149. Olivier K.N., et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 167 6 (2003) 835-840 [Epub 2002 Nov 14]
150. Ramsey B.W., et al. The effect of respiratory viral infections on patients with cystic fibrosis. Am J Dis Child 143 6 (1989) 662-668
151. Wang E.E., et al. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 311 26 (1984) 1653-1658
152. Tarran R., et al. Normal and cystic fibrosis airway surface liquid homeostasis: the effects of phasic shear stress and viral infections. J Biol Chem 280 42 (2005) 35751-35759 [Epub 2005 Aug 8]
153. Larson E.L., et al. Effect of antiseptic handwashing vs alcohol sanitizer on health care-associated infections in neonatal intensive care units. Arch Pediatr Adolesc Med 159 4 (2005) 377-383
154. Garner J.S. Guideline for isolation precautions in hospitals. Part I: evolution of isolation practices, Hospital Infection Control Practices Advisory Committee. Am J Infect Control 24 1 (1996) 24-31
155. Ensor E., et al. Is Burkholderia (Pseudomonas) cepacia disseminated from cystic fibrosis patients during physiotherapy?. J Hosp Infect 32 1 (1996) 9-15
156. Standaert T.A., et al. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest 114 2 (1998) 577-586
157. Reychler G., et al. In vitro evaluation of efficacy of 5 methods of disinfection on mouthpieces and facemasks contaminated by strains of cystic fibrosis patients. J Cyst Fibros 4 3 (2005) 183-187
158. Rutala W.A., et al. Antimicrobial activity of home disinfectants and natural products against potential human pathogens. Infect Control Hosp Epidemiol 21 1 (2000) 33-38
159. Sanborn M.R., Wan S.K., and Bulard R. Microwave sterilization of plastic tissue culture vessels for reuse. Appl Environ Microbiol 44 4 (1982) 960-964
160. Silva M.M., et al. Effectiveness of microwave irradiation on the disinfection of complete dentures. Int J Prosthodont 19 3 (2006) 288-293
161. Rutala W.A., et al. Efficacy of a washer-pasteurizer for disinfection of respiratory-care equipment. Infect Control Hosp Epidemiol 21 5 (2000) 333-336
162. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145 10 (2006) 758-764
163. Peach S.L., et al. Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis. J Clin Pathol 39 9 (1986) 1013-1018
164. Yahav J., Samra Z., Blau H., et al. Helicobacter pylori and Clostridium difficile in cystic fibrosis patients. Dig Dis Sci 51 12 (2006) 2274-2279
165. Binkovitz L.A., et al. Atypical presentation of Clostridium difficile colitis in patients with cystic fibrosis. AJR Am J Roentgenol 172 2 (1999) 517-521
166. Zuckerman J.B., et al. Measurement of bacterial shedding in CF clinics. Pediatr Pulmonol Suppl 28 (2005) 301
167. Steinkamp G., and Ullrich G. Different opinions of physicians on the importance of measures to prevent acquisition of Pseudomonas aeruginosa from the environment. J Cyst Fibros 2 4 (2003) 199-205
168. Griffiths A.L., et al. Cystic fibrosis patients and families support cross-infection measures. Eur Respir J 24 3 (2004) 449-452
169. Russo K., Donnelly M., and Reid A.J. Segregation: the perspectives of young patients and their parents. J Cyst Fibros 5 2 (2006) 93-99 [Epub 2006 Jan 31]
170. Mahadeva R., et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. Br Med J 316 7147 (1998) 1771-1775
171. Zhou J., et al. Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis. J Clin Microbiol 44 4 (2006) 1547-1549
172. Yankaskas J.R., et al. Cystic fibrosis adult care: consensus conference report. Chest 125 1 Suppl (2004) 1S-39S
173. Armstrong D.S., et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 166 7 (2002) 983-987
174. O'Carroll M.R., et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J 24 1 (2004) 101-106
175. Edenborough F.P., et al. Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need for segregation. J Cyst Fibros 3 1 (2004) 37-44
176. Lewis D.A., et al. Identification of DNA markers for a transmissible Pseudomonas aeruginosa cystic fibrosis strain. Am J Respir Cell Mol Biol 33 1 (2005) 56-64 [Epub 2005 Apr 15]
177. Panagea S., et al. PCR-based detection of a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. Mol Diagn 7 3-4 (2003) 195-200
178. Smart C.H., et al. Development of a diagnostic test for the Midlands 1 cystic fibrosis epidemic strain of Pseudomonas aeruginosa. J Med Microbiol 55 Pt 8 (2006) 1085-1091
179. Parsons Y.N., et al. Use of subtractive hybridization to identify a diagnostic probe for a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. J Clin Microbiol 40 12 (2002) 4607-4611
180. Zuercher A.W., et al. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol Med Microbiol 47 2 (2006) 302-308
181. Pier G. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Expert Rev Vaccines 4 5 (2005) 645-656
182. Lang A.B., et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 23 6 (2004) 504-510
183. Vianelli N., et al. Resolution of a Pseudomonas aeruginosa outbreak in a hematology unit with the use of disposable sterile water filters. Haematologica 91 7 (2006) 983-985 [Epub 2006 Jun 1]
184. Exner M., et al. Prevention and control of health care-associated waterborne infections in health care facilities. Am J Infect Control 33 5 Suppl 1 (2005) S26-S40
185. Head N.E., and Yu H. Cross-sectional analysis of clinical and environmental isolates of Pseudomonas aeruginosa: biofilm formation, virulence, and genome diversity. Infect Immun 72 1 (2004) 133-144
186. Lester M.K., et al. Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care 49 12 (2004) 1504-1508